Interpace to Present at the American College of Gastroenterology Conference
Interpace hosts 2nd Annual Fellow Programs
PARSIPPANY, NJ, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Interpace (IDXG) announced today that it will be presenting new data on the performance of its molecular thyroid and GI products at an industry known scientific international meeting. The American College of Gastroenterology annual meeting is held on October 27-30 in San Antonio, Texas and is one of the largest gatherings of gastroenterologists and endoscopists. These are two key targets for Interpace’s PancraGEN® test for early detection of cancer in indeterminate pancreatic cysts, solid lesions, and biliary structures. The PancraGEN publication entitled “Serial molecular testing of pancreatic cyst fluid over time: progression and regression” highlights the Company’s unique clinical and molecular database of patient results, examining 2,167 patients with pancreatic cysts that underwent multiple PancraGEN tests over time. The results support the high negative predictive value of PancraGEN, showing that the majority of cases (92%) initially found to have low risk PancraGEN results remained low risk at follow-up. The small portion of patients that did progress only progressed to moderate risk levels, where risk most often regressed to low risk over time.
In addition to the poster, Interpace will host its second annual Fellows program. The keynote speakers will be Dr. Tamas Gonda, Columbia University, and Dr. James Farrell, Yale University. Dr.’s Gonda and Farrell are going to be discussing their peer-reviewed published work on the utility of DNA analysis in managing patients with pancreatic cysts, describing molecular results of patients who have undergone PancraGEN® testing and how those results can be used to impact patient management decisions.
Interpace is a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.
Interpace’s Diagnostic Business is a fully integrated commercial and bioinformatics business unit that provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has four commercialized molecular tests and one test in a clinical evaluation process (CEP): PancraGEN® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT® for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR® for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDX® that differentiates lung cancer of primary vs. metastatic origin. In addition, BarreGEN® for Barrett’s Esophagus, is currently in a clinical evaluation program whereby we gather information from physicians using BarreGEN® to assist us in positioning the product for full launch, partnering and potentially supporting reimbursement with payers.
Interpace’s Biopharma Business provides pharmacogenomics testing, genotyping, biorepository and other customized services to the pharmaceutical and biotech industries. The Biopharma Business also advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care.
For more information, please visit Interpace’s website at www.interpacediagnostics.com.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company's future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to the fact that there is no assurance the acquisition of the BioPharma business of Cancer Genetics, Inc. will be successfully integrated with the Company, or that the potential benefits of the acquisition, including future revenues, will be successfully realized. Additionally, all forward-looking statements are subject to the “Risk Factors” detailed from time to time in the Company's most recent Annual Report on Form 10-K, Current Reports on Form 8-K and Quarterly Reports on Form 10-Q. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Investor Relations - Edison Group
Released October 24, 2019